Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 6/20 | 0.46 |
| ▸ | GSK3B | P49841 | 4/20 | 0.43 |
| ▸ | CDK8 | P49336 | 2/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 4/20 | 0.41 |
| ▸ | FLT1 | P17948 | 1/20 | 0.41 |
| ▸ | CETP | P11597 | 2/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12015918 | 0.94 | GSK3B (0.48) | RAF1GSK3BCDK8NOTUMKDR | |
| Trifluoroacetic Acid SCHEMBL3531719 | 0.91 | KDR (0.49) | RAF1GSK3BCDK8NOTUMKDR | |
| Trifluoroacetic Acid SCHEMBL3534184 | 0.91 | RAF1 (0.51) | RAF1GSK3BCDK8NOTUMKDR | |
| SCHEMBL12015917 | 0.84 | KDR (0.54) | RAF1GSK3BNOTUMKDRFLT1 | |
| SCHEMBL12015915 | 0.84 | RAF1 (0.49) | RAF1GSK3BCDK8NOTUMKDR | |
| Trifluoroacetic Acid SCHEMBL3530866 | 0.82 | KDR (0.48) | RAF1GSK3BCDK8NOTUMKDR | |
| Trifluoroacetic Acid SCHEMBL3532518 | 0.82 | RAF1 (0.63) | RAF1GSK3BCDK8KDRFLT1 | |
| SCHEMBL12057526 | 0.79 | GSK3B (0.51) | GSK3B | |
| SCHEMBL12075107 | 0.79 | GSK3B (0.46) | GSK3BKDRFLT1 | |
| SCHEMBL12015909 | 0.78 | RAF1 (0.67) | RAF1GSK3BCDK8KDRFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130243754-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | TARGEGEN, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| US-8372971-B2 | Heterocyclic compounds and methods of use | TARGEGEN, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| EP-2532653-A1 | Benzo[1,2,4]triazines as protein kinase modulators | Targegen, Inc. (US) | 2012-12-12 | — | — | EP | disclosed |
| US-8084618-B2 | Heterocyclic compounds and methods of use | TARGEGEN, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-20100330069-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | TARGEGEN, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-7652051-B2 | Heterocyclic compounds and methods of use | TARGEGEN, INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-20060079526-A1 | Heterocyclic compounds and methods of use | TARGEGEN, INC. (US) | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130243754-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AADAC, NISCH, PAICS | RAF1 2602/4885GSK3B 2586/4885CDK8 110/4885 |
| US-20060079526-A1 | Heterocyclic compounds and methods of use | AADAC, NISCH, PAICS | RAF1 2602/4885GSK3B 2586/4885CDK8 110/4885 |
| US-20100330069-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AADAC, NISCH, PAICS | RAF1 2602/4885GSK3B 2586/4885CDK8 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.